Dicle Sahin

Dicle Sahin

Auto-generated profile, based on publicly available information

Dicle Sahin

Department of Pharmaceutical Research and Development, Institute of Health Sciences Süleyman Demirel University Isparta Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
MCMedine Canakdag
Medine Canakdag
Mehran Feizi-DehnayebiMehran Feizi-Dehnayebi
Mehran Feizi-Dehnayebi
SKSevgi Kundu
Sevgi Kundu
DSDicle Sahin
Dicle Sahin
IIİlhan Özer İlhan
İlhan Özer İlhan
SASenem Akkoç
Senem Akkoç

26 December 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
DSDicle Sahin
Dicle Sahin
RKRemziye Aysun Kepekci
Remziye Aysun Kepekci
BTBurçin Türkmenoğlu
Burçin Türkmenoğlu
SASenem Akkoç
Senem Akkoç
Three new thymol-based molecules were synthesized and evaluated as anticancer, antimicrobial and antioxidant agents. Liver, colon, lung and prostate cancer cell lines were utilized in cytotoxicity tests. The results demonstrated that synthesized molecules had a cytotoxic effect against the screened cell lines. One of the molecules (4a) was found to have a higher efficacy towards the colon cancer cell line (DLD-1) with an IC50 value of 12.39 µM and the other (4c) towards the prostate cancer cell line (PC3) with an IC50 value of 7.67 µM than the positive control drug cisplatin. To assess the antimicrobial activity of molecules (4a-c), Gram-positive bacteria, Gram-negative bacteria and yeast were subjected to agar disc diffusion and broth microdilution assays. The investigation of antioxidant potential was conducted using the DPPH radical scavenging activity assay. While all compounds displayed strong cytotoxic and antioxidant properties, they exhibited only moderate antimicrobial activity. Molecular docking studies were performed on epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR-2), focal adhesion kinase (FAK), B-Raf and phosphoinositide 3-kinase (PI3K). The binding energies and interactions obtained from the docking results of compounds (4a-c) supported the experimental results. Drug similarity rates and pharmacokinetic properties were analyzed with the absorption, distribution, metabolism and excretion (ADME) method. Geometric parameters such as chemical potential (µ), electrophilicity index (ω) and chemical softness (σ) of compounds (4a-c) were calculated using the 6-31*G basis set B3LYP method.Communicated by Ramaswamy H. Sarma.

5 February 2025 in Applied Organometallic Chemistry
Verified
Journal Article
Open access
HSHatice Gamze Sogukomerogullari
Hatice Gamze Sogukomerogullari
BDBülent Dede
Bülent Dede
DSDicle Sahin
Dicle Sahin
SASenem Akkoç
Senem Akkoç
In this study, mononuclear Ni(II), Cu(II), Zn(II), and Pd(II) complexes of a diimine molecule (H2L) were synthesized, and their structures were elucidated by NMR, FT‐IR, UV–Vis, ICP‐OES, molar conductivity, magnetic susceptibility, and elemental analysis techniques. Stoichiometric and spectroscopic data revealed that the complexes have a metal:ligand ratio of 1:1 and the Schiff base coordinates with the metal(II) ion via nitrogen atoms of two imine groups and oxygen anions of two phenolate moieties and have a square planar geometry. The cytotoxic activity properties of the ligand and its metal complexes were screened in two distinct cancer cell lines: lung (A549) and colon (DLD‐1). The optimized molecular geometries, molecular electrostatic potential diagrams, total density of states plots, and frontier molecular orbitals of the H2L ligand and all metal(II) complexes at the ground level were calculated using density functional theory. The LANL2DZ basis set containing the effective core potentials for transition metals was used for quantum chemical calculations. The calculations supported the square planar geometry of the metal(II) ions in the complexes. The potential of all molecules to inhibit the MLK4 kinase domain (PDB ID: 4UYA) involved in cancer progression was examined by molecular docking study and the best inhibition activity belonged to the H2L molecule with a binding energy of −10.8 kcal/mol. The stability of the H2L–4UYA complex in physiological media was also confirmed by molecular dynamics simulation for 100 ns.